# First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras

> **NCT01057017** · PHASE2 · TERMINATED · sponsor: **Brown University** · enrollment: 5 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** intervention

## Key facts

- **NCT ID:** NCT01057017
- **Lead sponsor:** Brown University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2011-04
- **Final completion:** 2011-12
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** possible lack of efficacy
- **Last updated:** 2020-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01057017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01057017, "First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01057017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*